Role of immunotherapy for renal cell cancer in 2011

Saby George, Roberto Pili, Michael A. Carducci, Jenny J. Kim

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

High-dose interleukin-2 (IL-2) and interferon were the most commonly administered therapies before the recent introduction of targeted agents, including vascular endothelial growth factor and mammalian target of rapamycin pathway inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. Lastly, improved understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of immunotherapy in the management of metastatic RCC.

Original languageEnglish (US)
Pages (from-to)1011-1018
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume9
Issue number9
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interferons
Interleukin-2
Sirolimus
Vascular Endothelial Growth Factor A
Disease-Free Survival
Therapeutics
Bevacizumab

Keywords

  • Immunotherapy
  • Interleukin
  • Renal cell cancer
  • Tumor immunity

ASJC Scopus subject areas

  • Oncology

Cite this

Role of immunotherapy for renal cell cancer in 2011. / George, Saby; Pili, Roberto; Carducci, Michael A.; Kim, Jenny J.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 9, No. 9, 01.09.2011, p. 1011-1018.

Research output: Contribution to journalReview article

George, Saby ; Pili, Roberto ; Carducci, Michael A. ; Kim, Jenny J. / Role of immunotherapy for renal cell cancer in 2011. In: JNCCN Journal of the National Comprehensive Cancer Network. 2011 ; Vol. 9, No. 9. pp. 1011-1018.
@article{cae81d4c913d42c3bcaade094ec52915,
title = "Role of immunotherapy for renal cell cancer in 2011",
abstract = "High-dose interleukin-2 (IL-2) and interferon were the most commonly administered therapies before the recent introduction of targeted agents, including vascular endothelial growth factor and mammalian target of rapamycin pathway inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. Lastly, improved understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of immunotherapy in the management of metastatic RCC.",
keywords = "Immunotherapy, Interleukin, Renal cell cancer, Tumor immunity",
author = "Saby George and Roberto Pili and Carducci, {Michael A.} and Kim, {Jenny J.}",
year = "2011",
month = "9",
day = "1",
language = "English (US)",
volume = "9",
pages = "1011--1018",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Role of immunotherapy for renal cell cancer in 2011

AU - George, Saby

AU - Pili, Roberto

AU - Carducci, Michael A.

AU - Kim, Jenny J.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - High-dose interleukin-2 (IL-2) and interferon were the most commonly administered therapies before the recent introduction of targeted agents, including vascular endothelial growth factor and mammalian target of rapamycin pathway inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. Lastly, improved understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of immunotherapy in the management of metastatic RCC.

AB - High-dose interleukin-2 (IL-2) and interferon were the most commonly administered therapies before the recent introduction of targeted agents, including vascular endothelial growth factor and mammalian target of rapamycin pathway inhibitors. Although the new agents result in a progression-free survival benefit, high-dose IL-2 remains the only agent with proven efficacy in producing durable complete and partial responses in patients with metastatic renal cell carcinoma (RCC). Furthermore, although the use of single-agent interferon has decreased significantly since the introduction of targeted therapy, it remains in the frontline setting in combination with bevacizumab as a result of 2 large phase III trials. Lastly, improved understanding of immune regulation has led to the advancement of targeted immunotherapy using immune checkpoint inhibitors that have shown promising activity and are moving forward in clinical development. This article focuses on the current status of immunotherapy in the management of metastatic RCC.

KW - Immunotherapy

KW - Interleukin

KW - Renal cell cancer

KW - Tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=80053038782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053038782&partnerID=8YFLogxK

M3 - Review article

C2 - 21917625

AN - SCOPUS:80053038782

VL - 9

SP - 1011

EP - 1018

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 9

ER -